
Cipla shares fall 7% on USFDA observations for Pithampur unit
The U.S. drug regulator has issued Form 483 with 8 observations after the inspection of its Pithampur manufacturing facilities from February 6-17.
The U.S. drug regulator has issued Form 483 with 8 observations after the inspection of its Pithampur manufacturing facilities from February 6-17.
USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved, says Cipla.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
Sun Pharma will sell Molnupiravir under the brand name Molxvir in India, Torrent Pharma will sell it as Molnutor, while Cipla will market it as Cipmolnu.
Home-grown smaller players are giving biggies a run for their money in the US generics market.
A great pharma and medical supply chain, large population, intent among health professionals to innovate, and willingness among customers to try new solutions will ensure the sector's success.
The pandemic is a timely and apt reminder to pay heed to our respiratory health, and particularly the lungs.
India’s pharma industry is reimagining itself. This is not just borne out of the necessities brought forth by the pandemic, but is a blueprint to thrive and to succeed in this new world.
2020 was a transformative year, with Covid-19 altering the corporate landscape like never before. But now that 2021 is here, how different will it turn out to be? Ten leaders of India Inc. weigh in.
As the world awaits a panacea for Covid-19, pharma companies have their feet firmly on the accelerator to get people a safe vaccine to stem the spiral of death and illness looming over humanity.